Results 1 to 10 of about 963 (180)

Elucidation of Inverse Agonist Activity of Bilastine [PDF]

Pharmaceutics, 2020
H1-antihistamines antagonize histamine and prevent it from binding to the histamine H1 receptor (H1R). Some of them also act as inverse agonists, which are more potent than pure antagonists because they suppress the constitutive H1R activity.
Hiroyuki Mizuguchi, Tomoharu Wakugawa, Hisato Sadakata, Seiichiro Kamimura, Mai Takemoto, Tomomi Nakagawa, Masami Yabumoto, Yoshiaki Kitamura, Noriaki Takeda, Hiroyuki Fukui   +9 more
doaj   +4 more sources

Expert opinion on the role of bilastine and bilastine-montelukast combination in the management of allergic rhinitis: An Indian perspective

The Journal of Association of Chest Physicians, 2023
In India, the burden of allergic rhinitis (AR) is enormous, comprising 55% of all patients with allergies. Intranasal corticosteroids are the recommended first-line therapy for patients with moderate-to-severe AR, particularly when nasal congestion is ...
Subir Jain, Sarika Verma, Santhalingam Balamurugan, K.R. Bharath Kumar Reddy, D.J. Christopher   +4 more
doaj   +3 more sources

A comparative study of efficacy and tolerability of cetirizine and bilastine in patients of allergic rhinitis: An open-label, randomized, parallel-group study [PDF]

Perspectives in Clinical Research
Purpose: Allergic rhinitis (AR) is a type 1 allergic disease of the nasal mucosa, characterized by paroxysmal repetitive sneezing, watery rhinorrhea, and nasal blockage with the prevalence of 25% worldwide.
Sneha P. Pawar, Punam A. Gosavi, Mrunalini Vinay Kalikar   +2 more
doaj   +2 more sources

A prospective, observational study of efficacy and safety of desloratadine and bilastine in patients of chronic spontaneous urticaria [PDF]

Perspectives in Clinical Research
Purpose: Urticaria is a disease where there is development of short-lived itchy wheals (hives), angioedema, or both.[1] With a lifetime prevalence of up to 22%, it is a widespread skin disorder that affects the general population.
Suchi Bansod, Mrunalini Vinay Kalikar, Smita Sontakke, Jayesh Ishwardas Mukhi, Bhagyashree Babanrao Supekar, Sneha P. Pawar, Divya Raj   +6 more
doaj   +2 more sources

Efficacy and Safety of Bilastine in the Treatment of Allergic Rhinitis: A Systematic Review and Meta-analysis

Frontiers in Pharmacology, 2022
Bilastine is a non-sedating second generation H1 oral antihistamine (OAH) for treating allergic rhinitis (AR) patients. The effect of bilastine has not previously been evaluated in a meta-analysis. The aim of this review was to determine the efficacy and
Baharudin Abdullah, Mohd Khairi Md Daud, Mohd Noor Norhayati   +2 more
exaly   +3 more sources

Efficacy and safety of bilastine in Japanese patients with chronic spontaneous urticaria: A multicenter, randomized, double-blind, placebo-controlled, parallel-group phase II/III study

Allergology International, 2017
Background: Bilastine, a novel non-sedating second-generation H1-antihistamine, has been widely used in the treatment of allergic rhinoconjunctivitis and urticaria with a recommended dose of 20 mg once daily in most European countries since 2010.
Michihiro Hide, Masutaka Furue, Akiko Yagami   +2 more
exaly   +3 more sources

Effectiveness, Safety, and Tolerability of Bilastine Up-Dosing in Chronic Spontaneous Urticaria Uncontrolled with Licensed Doses of Other Second-Generation Antihistamines—An Institution-Based, Open-Label, Single-Group Longitudinal Trial [PDF]

Indian Dermatology Online Journal
Background: Bilastine 20 mg daily is a second-generation antihistamine (sgAH) approved for chronic spontaneous urticaria (CSU). Up-dosing to 40 or 80 mg daily is recommended in uncontrolled patients.
Sankha S. Chakraborty, Indrashis Podder, Manisha Das, Arunima Dhabal   +3 more
doaj   +2 more sources

The new bilastine eye drop formulation protects against conjunctival dehydration and promotes corneal wound healing in a comparative in vitro study [PDF]

Scientific Reports
Bilastine is a non-sedating, highly selective H1-antihistamine with proven efficacy and safety in treating allergic rhinoconjunctivitis and urticaria in adults and children.
Eider Arana, Ana Gonzalo, Noelia Andollo, Miguel Pérez-Garrastachu, Francisco Otero-Espinar, Victoria Díaz-Tomé, Felipe Goñi-de-Cerio, Paloma Gómez-Fernández, Gonzalo Hernández, Tatiana Suárez-Cortés   +9 more
doaj   +2 more sources

Effectiveness, safety, and cost-effectiveness of fixed-dose combination of montelukast–bilastine versus montelukast–levocetirizine in allergic rhinitis: A prospective, randomized, open-label, parallel-group study [PDF]

Perspectives in Clinical Research
Introduction: Several fixed-dose combinations (FDCs) have been available for the treatment of allergic rhinitis (AR), of which montelukast and levocetirizine is one of the highly prescribed FDC.
Ganesh Natthuji Dakhale, Chaitali A. Chindhalore, Mohit Kumar, Vijay Bidkar   +3 more
doaj   +2 more sources

Efficacy and safety of switching to bilastine, an H1-antihistamine, in patients with refractory chronic spontaneous urticaria (H1-SWITCH): a multicenter, open-label, randomized, parallel-group comparative study [PDF]

Frontiers in Immunology
BackgroundFor treating patients with refractory chronic spontaneous urticaria (CSU) resistant to standard doses of 2nd generation H1-antihistamines (H1AH) the International and Japanese guidelines recommend increasing H1AH dose.
Atsushi Fukunaga, Atsushi Fukunaga, Yasumasa Kakei, Yasumasa Kakei, Sae Murakami, Yuji Kan, Koji Masuda, Masatoshi Jinnin, Ken Washio, Hiroo Amano, Tohru Nagano, Akihisa Yamamoto, Toshihiro Otsuka, Shunsuke Takahagi, Motoi Takenaka, Naoko Ishiguro, Koremasa Hayama, Naoko Inomata, Yukinobu Nakagawa, Akiko Sugiyama, Michihiro Hide, Michihiro Hide   +21 more
doaj   +2 more sources